BOLD
Audentes Therapeutics, Inc
BOLD
BOLD
Delisted
BOLD was delisted on the 14th of January, 2020.
139 hedge funds and large institutions have $1.71B invested in Audentes Therapeutics, Inc in 2019 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
139
Holders Change
+13
Holders Change %
+10.32%
% of All Funds
3.01%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.17%
New
27
Increased
49
Reduced
41
Closed
14
Calls
$3.87M
Puts
$1.18M
Net Calls
+$2.69M
Net Calls Change
+$2.09M
Top Buyers
| 1 |
GGHC
1
Gilder Gagnon Howe & Co
New York
|
$63.2M |
| 2 |
BBA
2
Baker Bros. Advisors
New York
|
$66.9M |
| 3 |
BB
3
BB Biotech
Schaffhausen,
Switzerland
|
$53.4M |
| 4 |
RG
4
Redmile Group
San Francisco,
California
|
$107M |
| 5 |
5
Jennison Associates
New York
|
$52.6M |
Top Sellers
| 1 |
PHS
1
PFM Health Sciences
San Francisco,
California
|
$79.2M |
| 2 |
2
Citadel Advisors
Miami,
Florida
|
$13.6M |
| 3 |
NC
3
Nexthera Capital
New York
|
$9.78M |
| 4 |
4
Fidelity Investments
Boston,
Massachusetts
|
$103M |
| 5 |
5
Morgan Stanley
New York
|
$331K |